HealthQuill Health
Danish drugmaker Novo Nordisk will terminate its agreement with a US-based telehealth company, Hims & Hers Health Inc., to sell its weight-loss drug, Wegovy.
Drugs Health Medical

Novo terminates agreement with Hims & Hers to sell weight-loss drug

HQ Team June 23, 2025: Danish drugmaker Novo Nordisk will terminate its agreement with a US-based telehealth company, Hims & Hers Health Inc.,.

Read More
US-based researchers at Northeastern University are trying to unravel how axolotls, a small salamander, a smooth-skinned amphibian that often lives in watery or damp places, regrow entire limbs and even organs, and may hold the secret to replicating it in humans.
Climate Health Research

Axolotls may hold the key to human organ regeneration: US researchers

 HQ Team June 23, 2025: US-based researchers at Northeastern University are trying to unravel how axolotls, a small salamander, a smooth-skinned amphibian that.

Read More
Private corporations stand to profit from smartphone apps that track menstrual cycles as they provide a ‘gold mine’ for consumer profiling, collecting information on everything from exercise, diet and medication to sexual preferences, hormone levels and contraception use, according to a report.
Health Medical Research

‘Menstrual tracking data being used to control people’s reproductive lives’

HQ Team June 23, 2025: Private corporations stand to profit from smartphone apps that track menstrual cycles as they provide a ‘gold mine’.

Read More
Novo Nordisk A/S’s data from a clinical trial of a weight-loss medicine, treating overweight and obese adult participants, showed patients lost about 23% of their body weight compared to a dummy group’s 2-3%.
Drugs Health Pharma

Novo Nordisk’s obesity drug CagriSema cuts weight by 23%

HQ Team June 22, 2025: Novo Nordisk A/S’s data from a clinical trial of a weight-loss medicine, treating overweight and obese adult participants,.

Read More
Madrigal Pharmaceuticals EU Limited's therapy to treat adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) got a conditional marketing authorisation in the European Union. 
Drugs Health Medical

Madrigal’s therapy to treat MASH in adults gets EU’s initial nod

HQ Team June 22, 2025: Madrigal Pharmaceuticals EU Limited’s therapy to treat adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) got a conditional marketing.

Read More
Supernus Pharmaceuticals, Inc. will acquire Sage Therapeutics, Inc. for a total consideration of up to $795 million, to gain access to a medicine to treat postpartum depression.
Drugs Health Pharma

Supernus Pharma to acquire Sage Therapeutics for $795 million all cash

HQ Team June 22, 2025: Supernus Pharmaceuticals, Inc. will acquire Sage Therapeutics, Inc. for a total consideration of up to $795 million, as.

Read More
Novo Nordisk’s experimental weight loss medicine amycretin helped overweight and obese adults lose up to 24% of their weight in a small study, according to a company statement.
Drugs Health Pharma

Novo Nordisk’s amycretin drug helps obese adults lose 24% weight

HQ Team June 21, 2025: Novo Nordisk’s experimental weight loss medicine amycretin helped overweight and obese adults lose up to 24% of their.

Read More
Novo Nordisk’s medicine Wegovy, at a higher dose, resulted in an average weight loss of 21% during trials in people with obesity compared to a dummy drug, the company stated.
Drugs Health Pharma

Wegovy’s weight-loss efficacy improves with higher dosage

HQ Team June 21, 2025: Novo Nordisk’s medicine Wegovy, at a higher dose, resulted in an average weight loss of 21% during trials.

Read More
The UK Health Security Agency and the Met Office have issued an amber heat-health alert for all regions of England for the next four days.
Climate Health Medical

UK health agency, Met Office, issues an amber alert as temperatures rise

HQ Team June 19, 2025: The UK Health Security Agency and the Met Office have issued an amber heat-health alert for all regions.

Read More
Eli Lilly and Company will acquire gene-editing startup Verve Therapeutics, Inc. for up to $1.3 billion to pocket an early-stage experimental therapy and to develop once-in-a-lifetime treatments for cardiovascular diseases.
Drugs Health Pharma

Eli Lilly to buy Verve for $1.3 billion, expands heart therapy segment

HQ Team June 19, 2025: Eli Lilly and Company will acquire gene-editing startup Verve Therapeutics, Inc. for up to $1.3 billion to pocket an.

Read More